<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409234111
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EDARBYCLOR 40 MG/25 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZILSARTAN MEDOXOMIL,CHLORTHALIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC Sult" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC Sult
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Edarbyclor is a prescription medicine that contains azilsartan medoxomil, an angiotensin receptor blocker (ARB) and chlorthalidone, a water pill (diuretic).</p><p>Edarbyclor is used to treat high blood pressure (hypertension):</p><ul><li>When one medicine to lower your high blood pressure is not enough</li><li>As the first medicine to lower your high blood pressure if your doctor decides you are likely to need more than one medicine.</li></ul><p>It is not known if Edarbyclor is safe and effective in children under 18 years of age.</p><p><strong>What is high blood pressure (hypertension)?</strong></p><p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too great.</p><p>High blood pressure makes the heart work harder to pump blood through the body and causes damage to the blood vessels. Edarbyclor tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower your blood pressure may lower your chance of having a stroke or heart attack.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Edarbyclor:</strong></p><ul><li>If you make less urine because of kidney problems</li></ul><p><strong>Warnings and Precautions </strong></p><p>Before you take Edarbyclor, tell your doctor:</p><ul><li>If you have been told that you have abnormal body salt (electrolytes) levels in your blood</li><li>If you have liver or kidney problems</li><li>If you have heart problems or stroke</li><li>If you are vomiting or have diarrhea</li><li>If you have gout</li><li>If you are pregnant or plan to become pregnant.</li><li>If you are breastfeeding or plan to breastfeed. It is not known if Edarbyclor passes into your breast milk. You and your doctor should decide if you will take Edarbyclor or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take Edarbyclor.</li></ul><p><strong>Other medicines and Edarbyclor</strong></p><p>Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.</p><p>Especially tell your doctor if you take:</p><ul><li>Other medicines used to treat your high blood pressure or heart problem</li><li>Water pills (diuretics)</li><li>Lithium carbonate, lithium citrate</li><li>Digoxin</li></ul><p>Ask your doctor if you are not sure if you are taking a medicine listed above.</p><p>Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist when you get a new medicine.</p><p><strong>Edarbyclor with food</strong></p><p>Edarbyclor can be taken with or without food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Before you take Edarbyclor, tell your doctor:</p><ul><li>If you are pregnant or plan to become pregnant.</li><li>If you are breastfeeding or plan to breastfeed. It is not known if Edarbyclor passes into your breast milk. You and your doctor should decide if you will take Edarbyclor or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take Edarbyclor.</li></ul><p><strong>Driving and using machines </strong></p><p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Take Edarbyclor exactly as your doctor tells you to.</li><li>Your doctor will tell you how much Edarbyclor to take and when to take it.</li><li>Your doctor may prescribe other medicines for you to take along with Edarbyclor to treat your high blood pressure.</li><li>Edarbyclor can be taken with or without food.</li></ul><p><strong>If you take more Edarbyclor than you should</strong></p><p>If you take too much Edarbyclor and have symptoms of low blood pressure (hypotension) and dizziness, call your doctor for advice. See &ldquo;Possible side effects&rdquo;</p><p><strong>If you forgot to take Edarbyclor</strong></p><p>If you miss a dose, take it later in the same day. Do not take more than 1 dose of Edarbyclor in a day.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Edarbyclor may cause serious side effects, including:</p><ul><li>Low blood pressure (hypotension) and dizziness is most likely to happen if you also:</li></ul><p>-&nbsp;Take water pills (diuretics)</p><p>-&nbsp;Are on a low-salt diet</p><p>-&nbsp;Take other medicines that affect your blood pressure</p><p>-&nbsp;Sweat a lot</p><p>-&nbsp;Get sick with vomiting or diarrhea</p><p>-&nbsp;Do not drink enough fluids</p><p>If you feel faint or dizzy, lie down and call your doctor right away. If you pass out (faint) have someone call your doctor or get medical help. Stop taking Edarbyclor.</p><ul><li>Kidney problems. Kidney problems may become worse in people that already have kidney disease. Some people have changes in blood tests for kidney function and may need a lower dose of Edarbyclor or may need to stop treatment with Edarbyclor. During treatment with Edarbyclor, certain people who have severe heart failure, narrowing of the artery to the kidney, or who lose too much body fluid such as with nausea, vomiting, bleeding, or trauma, may develop sudden kidney failure and in rare instances, death.</li><li>Fluid and body salt (electrolyte) problems. Tell your doctor if you get any of the following symptoms:</li></ul><p>-&nbsp;Dry mouth</p><p>-&nbsp;Thirst</p><p>-&nbsp;Lack of energy (lethargic)</p><p>-&nbsp;Weakness</p><p>-&nbsp;Drowsiness</p><p>-&nbsp;Confusion</p><p>-&nbsp;Seizures</p><p>-&nbsp;Muscle pain or cramps</p><p>-&nbsp;Restlessness</p><p>-&nbsp;Muscle tiredness (fatigue)</p><p>-&nbsp;Passing very little urine or passing large amounts of urine</p><p>-&nbsp;Fast or abnormal heartbeat</p><p>-&nbsp;Nausea and vomiting</p><p>-&nbsp;Constipation</p><ul><li>Increased uric acid levels in the blood. People who have increased levels of uric acid in the blood may develop gout. If you already have gout, tell your doctor about worsening of your gout symptoms.</li></ul><p>The most common side effects of Edarbyclor are:</p><ul><li>Dizziness, and</li><li>Tiredness</li></ul><p>These are not all the possible side effects with Edarbyclor. Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C. Store in the original package in order to protect from light and moisture.</p><p>Keep the container tightly closed.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are azilsartan medoxomil and chlorthalidone.</p><p>Each film-coated tablet of Edarbyclor 40 mg/12.5 mg Film-coated Tablets contains azilsartan medoxomil potassium equivalent to 40 mg azilsartan medoxomil and 12.5 mg chlorthalidone.</p><p>Each film-coated tablet of Edarbyclor 40 mg/25 mg Film-coated Tablets contains azilsartan medoxomil potassium equivalent to 40 mg azilsartan medoxomil and 25 mg chlorthalidone.</p><p>The other ingredients are: <em>Tablet core:</em> mannitol, microcrystalline cellulose, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crospovidone and magnesium stearate. <em>Tablet coat:</em> Hypromellose, talc, titanium dioxide, ferric oxide red and polyethylene glycol. <em>Printing ink:</em> Opacode black.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Edarbyclor 40 mg/12.5 mg Film-coated Tablet is a pale red round film-coated tablet with both “A/C” and “40/12.5” printed on one side in carton containing desiccated aluminum/aluminum blister packs.

Pack size: 28 film-coated tablets.

Edarbyclor 40 mg/25 mg Film-coated Tablet is a light red round film-coated tablet with both “A/C” and “40/25” printed on one side in carton containing desiccated aluminum/aluminum blister packs.

Pack size: 28 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: jpimedical@hikma.com</p><p><strong>Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC.</p><p>P.O. Box 42</p><p>Sult, Jordan</p><p>Tel: + (962-5)3492200</p><p>Fax: + (962-5)3492203&nbsp;</p><p><strong>Under licensed from</strong></p><p>Takeda Pharmaceuticals International AG,</p><p>Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2020; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ايداربيكلور هو دواء يتم صرفه بوصفة طبية يحتوي على أزيلسارتان<strong> </strong>ميدوكسوميل، وهو من حاصرات مستقبلات الأنجيوتينسن ويحتوي على كلورثاليدون، وهو من حبوب الماء (مدر للبول).</p><p dir="RTL">يستخدم ايداربيكلور لعلاج ارتفاع ضغط الدم (فرط ضغط الدم):</p><ul dir="rtl"><li>عندما لا يكفيك مجرد دواء واحد لعلاج ارتفاع ضغط الدم لديك</li><li>يستخدم بصفته الدواء الأول من أجل خفض ضغط الدم المرتفع لديك إذا قرر طبيبك أنك على الأرجح ستحتاج إلى أكثر من دواء واحد.</li></ul><p dir="RTL">ليس معروفاً ما إذا كان ايداربيكلور آمناً وفعّالاً لدى الأطفال الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL"><strong>ما هو ارتفاع ضغط الدم (فرط ضغط الدم)؟</strong></p><p dir="RTL">ضغط الدم هو القوة التي تسري في الأوعية الدموية عندما ينبض قلبك وعندما يستقر. فإذا كانت هذه القوة كبيرة للغاية فأنت لديك ارتفاع في ضغط الدم.</p><p dir="RTL">يجهد ارتفاع ضغط الدم القلب لكي يضخ الدم إلى الجسم ويلحق الضرر بالأوعية الدموية. يمكن لأقراص ايداربيكلور أن تساعد أوعيتك الدموية على الاسترخاء لكي ينخفض ضغط دمك. الأدوية التي تعمل على خفض ضغط دمك قد تقلل من فرص إصابتك بسكتة دماغية أو نوبة قلبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ايداربيكلور:</strong></p><ul dir="rtl"><li>إذا كنت تخرج كمية بول أقل بسبب مشاكل في الكلى</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">قبل تناول ايداربيكلور، أخبر طبيبك:</p><ul dir="rtl"><li>إذا تم إخبارك بأن مستويات أملاح الجسم (الكهارل) في دمك غير طبيعية.</li><li>إذا كنت تعاني من مشاكل في الكبد أو الكلى</li><li>إذا كنت تعاني من مشاكل في القلب أو لديك سكتة دماغية</li><li>إذا تعاني من قيء أو إسهال</li><li>إذا كنت تعاني من النقرس</li><li>إذا كنتِ حاملاً أو تخططين لذلك.</li><li>إذا كنتِ تقومين بالرضاعة الطبيعية أو تخططين لذلك. من غير المعروف ما إذا كان ايداربيكلور يمر في حليب الثدي. يجب أن تقرري أنتِ وطبيبكِ إذا ما كنتِ ستتناولين ايداربيكلور أو ستقومين بالرضاعة الطبيعية. يجب ألا تفعلي كلا الأمرين معاً. تحدثي مع طبيبكِ عن أفضل طريقة لتغذية طفلكِ إذا كنت تتناولين ايداربيكلور.</li></ul><p dir="RTL"><strong>الأدوية الأخرى وايداربيكلور</strong></p><p dir="RTL">أخبر طبيبك عن جميع الأدوية التي تتناولها، بما في ذلك الأدوية التي يتم صرفها بوصفة طبية والأدوية التي لا تصرف بوصفة طبية، الفيتامينات، والمكملات العشبية.</p><p dir="RTL">أخبر طبيبك وخاصة إذا كنت تتناول:</p><ul dir="rtl"><li>أدوية أخرى تستخدم لعلاج ارتفاع ضغط الدم أو لعلاج مشكلة في القلب</li><li>حبوب الماء (مدرات البول)</li><li>كربونات الليثيوم، سيترات الليثيوم</li><li>ديجوكسين</li></ul><p dir="RTL">استشر طبيبك في حال عدم تأكدك إذا ما كنت تتناول أيّاً من الأدوية أعلاه.</p><p dir="RTL">كن على دراية بالأدوية التي تتناولها. واحتفظ بقائمة بها واعرضها على طبيبك أو الصيدلي عند حصولك على دواء جديد.</p><p dir="RTL"><strong>ايداربيكلور مع الطعام</strong></p><p dir="RTL">يمكن تناول ايداربيكلور مع الطعام أو بدونه.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">قبل تناول ايداربيكلور، أخبري طبيبك:</p><ul dir="rtl"><li>إذا كنتِ حاملاً أو تخططين لذلك.</li><li>إذا كنتِ تقومين بالرضاعة الطبيعية أو تخططين لذلك. من غير المعروف ما إذا كان ايداربيكلور يمر في حليب الثدي. يجب أن تقرري أنتِ وطبيبكِ إذا ما كنتِ ستتناولين ايداربيكلور أو ستقومين بالرضاعة الطبيعية. يجب ألا تفعلي كلا الأمرين معاً. تحدثي مع طبيبكِ عن أفضل طريقة لتغذية طفلكِ إذا كنت تتناولين ايداربيكلور.</li></ul><p dir="RTL"><strong>تأثير ايداربيكلور على القيادة واستخدام الآلات </strong></p><p dir="RTL">ليس له تأثير.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>قم دائماً بتناول ايداربيكلور كما وصفه لك طبيبك تماماً.</li><li>سيخبرك طبيبك بجرعات ايداربيكلور التي ستتناولها ومواعيدها.</li><li>قد يصف لك طبيبك أدوية أخرى تتناولها مع ايداربيكلور لعلاج ارتفاع ضغط الدم لديك.</li><li>يمكن تناول ايداربيكلور مع الطعام أو بدونه.</li></ul><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ايداربيكلور</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من ايداربيكلور وظهرت عليك أعراض انخفاض ضغط الدم (هبوط ضغط الدم) ودوخة، فاستشر طبيبك. انظر &quot;الآثار الجانبية المحتملة&quot;</p><p dir="RTL"><strong>إذا نسيت تناول ايداربيكلور</strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها لاحقاً في نفس اليوم. لا تتناول أكثر من جرعة واحدة من ايداربيكلور في اليوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يسبب ايداربيكلور آثاراً جانبية خطيرة، تشمل:</p><ul dir="rtl"><li>على الأرجح قد تحدث لك أعراض انخفاض ضغط الدم (هبوط ضغط الدم) ودوخة إذا كنت أيضاً:</li></ul><p dir="RTL">-&nbsp;تتناول حبوب الماء (مدرات البول)</p><p dir="RTL">-&nbsp;تسير على نظام غذائي منخفض الملح</p><p dir="RTL">-&nbsp;تتناول أدوية أخرى تؤثر على ضغط الدم لديك</p><p dir="RTL">-&nbsp;تتعرّق بشدة</p><p dir="RTL">-&nbsp;تعاني من إعياء مع قيء أو إسهال</p><p dir="RTL">-&nbsp;لا تشرب سوائل كافية</p><p dir="RTL">إذا شعرت بالإغماء أو الدوخة، فاستلق واتصل بطبيبك على الفور. إذا فقدت وعيك (أغمي عليك) فاطلب من أحدهم الاتصال بطبيبك أو الحصول على المساعدة الطبية. وتوقف عن تناول ايداربيكلور.</p><ul dir="rtl"><li>مشاكل في الكلى. قد تتفاقم مشاكل الكلى لدى الأشخاص المصابين فعلياً بمرض في الكلى. بعض الأشخاص تحدث لديهم تغيرات في اختبارات الدم لوظائف الكلى وقد يحتاجون جرعة أقل من ايداربيكلور أو التوقف عن العلاج بايداربيكلور. خلال فترة العلاج باستخدام ايداربيكلور، فإن بعض الأشخاص الذين يعانون من قصور شديد في القلب، ضيق الشريان الموصل إلى الكلى، أو الذين يفقدون الكثير من سوائل الجسم مثل الإصابة بالغثيان، القيء، النزيف، أو الصدمة، قد يصابون بفشل كلوي مفاجئ وفي بعض الحالات النادرة، الوفاة.</li><li>مشاكل في سوائل وأملاح الجسم (الكهارل). أخبر طبيبك إذا كنت تعاني من أي من الأعراض التالية:</li></ul><p dir="RTL">-&nbsp;جفاف بالفم</p><p dir="RTL">-&nbsp;عطش</p><p dir="RTL">-&nbsp;نقص في الطاقة (خمول)</p><p dir="RTL">-&nbsp;ضعف</p><p dir="RTL">-&nbsp;نعاس</p><p dir="RTL">-&nbsp;إرتباك</p><p dir="RTL">-&nbsp;نوبات صرع</p><p dir="RTL">-&nbsp;ألم أو تشنجات بالعضلات</p><p dir="RTL">-&nbsp;أرق</p><p dir="RTL">-&nbsp;إرهاق بالعضلات (تعب)</p><p dir="RTL">-&nbsp;التبول بمقدار ضئيل جداً أو بكميات كبيرة</p><p dir="RTL">-&nbsp;سرعة في ضربات القلب أو عدم انتظامها.</p><p dir="RTL">-&nbsp;غثيان وقيء</p><p dir="RTL">-&nbsp;إمساك</p><ul dir="rtl"><li>ارتفاع مستويات حمض اليوريك في الدم. الأشخاص الذين يعانون من ارتفاع مستويات حمض اليوريك في الدم قد يصبحون عرضة للإصابة بالنقرس. إذا كنت مصاباً بالنقرس بالفعل، أخبر طبيبك عن تفاقم أعراض النقرس لديك.</li></ul><p dir="RTL">الآثار الجانبية الأكثر شيوعاً لايداربيكلور هي:</p><ul dir="rtl"><li>الدوخة،</li><li>والتعب</li></ul><p dir="RTL">هذه ليست كل الآثار الجانبية المحتملة لايداربيكلور. أخبر طبيبك إذا كنت تعاني من أي أثر جانبي يزعجك أو لا يزول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">أبق العبوة محكمة الإغلاق.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعّالة هي أزيلسارتان ميدوكسوميل وكلورثاليدون.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من ايداربيكلور 40 ملغم/12.5 ملغم قرص مغطى بطبقة رقيقة على أزيلسارتان ميدوكسوميل البوتاسيوم يكافئ ٤۰ ملغم أزيلسارتان ميدوكسوميل و12.5 ملغم كلورثاليدون.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من ايداربيكلور 40 ملغم/25 ملغم قرص مغطى بطبقة رقيقة على أزيلسارتان ميدوكسوميل البوتاسيوم يكافئ ٤۰ ملغم أزيلسارتان ميدوكسوميل و25 ملغم كلورثاليدون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص: </em>مانيتول، سيلليلوز بلوري مكروي، حمض الفيوماريك، هيدروكسيد الصوديوم، هيدروكسي بروبيل السيلليلوز، كروسبوڤيدون وستيرات المغنيسيوم. <em>غلاف القرص:</em>&nbsp;هيبروميللوز، تالك، ثنائي أكسيد التيتانيوم، أكسيد الحديد الأحمر وغليكول متعدد الإيثيلين. <em>حبر الطباعة:</em> أوباكود أسود.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">ايداربيكلور 40 ملغم/12.5 ملغم قرص مغطى بطبقة رقيقة هو عبارة عن قرص دائري مغطى بطبقة رقيقة بلون أحمر باهت مطبوع على أحد جانبيه كل من &quot;A/C&quot; و&quot;40/12.5&quot; في عبوات كرتونية تحتوي على أشرطة من الألومنيوم/الألومنيوم المجفف.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong>حجم العبوة: 28 قرص مغطى بطبقة رقيقة.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong>ايداربيكلور 40 ملغم/25 ملغم قرص مغطى بطبقة رقيقة هو عبارة عن قرص دائري مغطى بطبقة رقيقة بلون أحمر فاتح مطبوع على أحد جانبيه كل من &quot;A/C&quot; و&quot;40/25&quot; في عبوات كرتونية تحتوي على أشرطة من الألومنيوم/الألومنيوم المجفف.</p><p dir="RTL" style="text-align:right">حجم العبوة: 28 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: jpimedical@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p dir="RTL">صندوق بريد 42</p><p dir="RTL">السلط، الأردن<br />هاتف: 3492200 (5-962) +<br />فاكس: 3492203 (5-962) +</p><p dir="RTL"><strong>بترخيص من</strong>&nbsp;</p><p dir="RTL">شركة تاكيدا الدوائية الدولية المحدودة،</p><p dir="RTL">سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2020/08؛ رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Edarbyclor 40 mg/25 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains azilsartan medoxomil potassium equivalent to 40 mg azilsartan medoxomil and 25 mg chlorthalidone.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Light red round film-coated tablet with both “A/C” and “40/25” printed on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Edarbyclor contains an angiotensin II receptor blocker (ARB) and a thiazide-like diuretic and is indicated for the treatment of hypertension, to lower blood pressure.</p><p>Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy.</p><p>Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.</p><p>Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor.</p><p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program&rsquo;s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p><p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.</p><p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p><p><strong>&nbsp;</strong>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.</p><p>The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor.</p><p>Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient&rsquo;s baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient&rsquo;s risk.</p><p>Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see section 5.1. Pharmacodynamic properties].</p><p>Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails.&nbsp;</p><p><strong>Figure 1.a Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8&nbsp;</strong></p><p><img alt="" width="410" height="288" src="data:image/png;base64,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" />&nbsp;</p><p><strong>Figure 1.b Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8</strong></p><p><img alt="" width="401" height="291" src="data:image/png;base64,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" />&nbsp;&nbsp;</p><p><strong>Figure 1.c Probability of Achieving Diastolic Blood Pressure &lt;90 mmHg at Week 8</strong></p><p><img alt="" width="433" height="302" src="data:image/png;base64,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" /></p><p><strong>Figure 1.d Probability of Achieving Diastolic Blood Pressure &lt;80 mmHg at Week 8</strong></p><p><img alt="" width="423" height="304" src="data:image/png;base64,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" /></p><p>For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of &lt;140 mm Hg (systolic) and 48% likelihood of achieving &lt;90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Dosing Information</em></strong></p><p>The recommended starting dose of Edarbyclor is 40/12.5 mg taken orally once daily. Most of the antihypertensive effect is apparent within 1 to 2 weeks. The dosage may be increased to 40/25 mg after 2 to 4 weeks as needed to achieve blood pressure goals. Edarbyclor doses above 40/25 mg are probably not useful.</p><p>Edarbyclor may be used to provide additional blood pressure lowering for patients not adequately controlled on ARB or diuretic monotherapy treatment. Patients not controlled with azilsartan medoxomil 80 mg may have an additional systolic / diastolic clinic blood pressure reduction of 13/6 mm Hg when switched to Edarbyclor 40/12.5 mg. Patients not controlled with chlorthalidone 25 mg may have an additional clinic blood pressure reduction of 10/7 mm Hg when switched to Edarbyclor 40/12.5 mg.</p><p>Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.</p><p>Patients titrated to the individual components (azilsartan medoxomil and chlorthalidone) may instead receive the corresponding dose of Edarbyclor.</p><p>Edarbyclor may be taken with or without food [see section 5. Pharmacological properties].</p><p>Edarbyclor may be administered with other antihypertensive agents as needed.</p><p><strong><em>Prior to Dosing</em></strong></p><p>Correct any volume depletion prior to administration of Edarbyclor, particularly in patients with impaired renal function or those treated with high doses of diuretics [see section 4.4. Special warnings and precautions for use].</p><p>Patients who experience dose-limiting adverse reactions on chlorthalidone may be switched to Edarbyclor, initially with a lower dose of chlorthalidone [see section 4.4. Special warnings and precautions for use].</p><p><strong><em>Pediatric Use</em></strong></p><p>Safety and effectiveness of Edarbyclor in pediatric patients under 18 years of age have not been established.</p><p><em>Neonates with a history of in utero exposure to Edarbyclor:</em></p><p>If oliguria or hypotension occurs, support blood pressure and renal function. Exchange transfusions or dialysis may be required.</p><p><strong><em>Geriatric Use</em></strong></p><p><em>Edarbyclor</em></p><p>No dose adjustment with Edarbyclor is necessary in elderly patients. Of the total patients in clinical studies with Edarbyclor, 24% were elderly (65 years of age or older); 5.7% were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see section 5. Pharmacological properties].</p><p><strong><em>Renal Impairment</em></strong></p><p><em>Edarbyclor</em></p><p>Safety and effectiveness of Edarbyclor in patients with severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) have not been established. No dose adjustment is required in patients with mild (eGFR 60-90 mL/min/1.73 m<sup>2</sup>) or moderate (eGFR 30-60 mL/min/1.73 m<sup>2</sup>) renal impairment.</p><p><em>Chlorthalidone</em></p><p>Chlorthalidone may precipitate azotemia.</p><p><strong><em>Hepatic Impairment</em></strong></p><p><em>Azilsartan medoxomil</em></p><p>No dose adjustment is necessary for subjects with mild or moderate hepatic impairment. Azilsartan medoxomil has not been studied in patients with severe hepatic impairment [see section 5. Pharmacological properties].&nbsp;</p><p><em>Chlorthalidone</em></p><p>Minor alterations of fluid and electrolyte balance may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Edarbyclor is contraindicated in patients with anuria [see section 4.4. Special warnings and precautions for use].
- Do not coadminister aliskiren with Edarbyclor in patients with diabetes [see section 4.5. Interaction with other medicinal products and other forms of interaction].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Fetal Toxicity</em></strong></p><p><em>Azilsartan medoxomil</em></p><p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Edarbyclor as soon as possible [see section 4.6. Fertility, pregnancy and lactation].</p><p><em>Chlorthalidone</em></p><p>Thiazides cross the placental barrier and appear in cord blood. Adverse reactions include fetal or neonatal jaundice and thrombocytopenia.</p><p><strong><em>Hypotension in Volume- or Salt-Depleted Patients</em></strong></p><p>In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Edarbyclor. Such patients are probably not good candidates to start therapy with more than one drug; therefore, correct volume prior to administration of Edarbyclor. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p><p><strong><em>Impaired Renal Function</em></strong></p><p><em>Edarbyclor</em></p><p>Monitor for worsening renal function in patients with renal impairment. Consider withholding or discontinuing Edarbyclor if progressive renal impairment becomes evident.</p><p><em>Azilsartan medoxomil</em></p><p>As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with Edarbyclor. In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death. Similar results may be anticipated in patients treated with Edarbyclor [see section 4.2, 4.5 and 5. Posology and method of administration, Interaction with other medicinal products and other forms of interaction, and Pharmacological properties].</p><p>In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of azilsartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results are expected.</p><p><em>Chlorthalidone</em></p><p>In patients with renal disease, chlorthalidone may precipitate azotemia. If progressive renal impairment becomes evident, as indicated by increased blood urea nitrogen, consider withholding or discontinuing diuretic therapy.</p><p><strong><em>Serum Electrolyte Imbalances</em></strong></p><p>Thiazide diuretics can cause hyponatremia and hypokalemia. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Hypokalemia is a dose-dependent adverse reaction that may develop with chlorthalidone. Co-administration of digitalis may exacerbate the adverse effects of hypokalemia. Monitor serum electrolytes periodically.</p><p>Edarbyclor attenuates chlorthalidone-associated hypokalemia. In patients with normal potassium levels at baseline, 1.7% of Edarbyclor-treated patients, 0.9% of azilsartan medoxomil-treated patients, and 13.4% of chlorthalidone-treated patients shifted to low potassium values (less than 3.4 mmol/L).</p><p><strong><em>Hyperuricemia</em></strong></p><p><em>Chlorthalidone</em></p><p>Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving chlorthalidone or other thiazide diuretics.</p><p><u>Patients taking Edarbyclor Film-coated Tablets should receive the following information and instructions: </u></p><p>Tell patients that if they miss a dose, they should take it later in the same day, but not to double the dose on the following day.</p><p><em>Pregnancy </em></p><p>Tell female patients of childbearing potential about the consequences of exposure to Edarbyclor during pregnancy. Discuss treatment options with women planning to become pregnant. Tell patients to report pregnancies to their physicians as soon as possible.</p><p><em>Symptomatic Hypotension </em></p><p>Advise patients to report light-headedness. Advise patients, if syncope occurs, to have someone call the doctor or seek medical attention, and to discontinue Edarbyclor.</p><p>Inform patients that dehydration from excessive perspiration, vomiting, or diarrhea may lead to an excessive fall in blood pressure. Inform patients to consult with their healthcare provider if these symptoms occur.</p><p><em>Renal Impairment </em></p><p>Inform patients with renal impairment that they should receive periodic blood tests to monitor their renal function while taking Edarbyclor.</p><p><em>Gout </em></p><p>Have patients report gout symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Edarbyclor</em></strong></p><p>The pharmacokinetics of azilsartan medoxomil and chlorthalidone are not altered when the drugs are co-administered.</p><p>No drug interaction studies have been conducted with other drugs and Edarbyclor, although studies have been conducted with azilsartan medoxomil and chlorthalidone.</p><p><strong><em>Azilsartan medoxomil</em></strong></p><p>No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin. Therefore, azilsartan medoxomil may be used concomitantly with these medications.</p><p><strong><em>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</em></strong></p><p>In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Edarbyclor and NSAID therapy.</p><p>The antihypertensive effect of Edarbyclor may be attenuated by NSAIDs, including selective COX-2 inhibitors.</p><p><strong><em>Dual Blockade of the Renin-Angiotensin System (RAS)</em></strong></p><p>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbyclor and other agents that affect the RAS.</p><p>Do not coadminister aliskiren with Edarbyclor in patients with diabetes. Avoid use of aliskiren with Edarbyclor in patients with renal impairment (GFR &lt;60 mL/min).</p><p><strong><em>Chlorthalidone</em></strong></p><p>Lithium renal clearance is reduced by diuretics, such as chlorthalidone, increasing the risk of lithium toxicity. Consider monitoring lithium levels when using Edarbyclor.</p><p><strong><em>Lithium</em></strong></p><p>Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>Pregnancy Category: D.</p><p>Use of drugs that affect the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Edarbyclor as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.</p><p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the reninangiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Edarbyclor, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Edarbyclor for hypotension, oliguria, and hyperkalemia [see section 4.2. Posology and method of administration].</p><p><strong><em>Nursing Mothers</em></strong></p><p>It is not known if azilsartan is excreted in human milk, but azilsartan is excreted at low concentrations in the milk of lactating rats and thiazide-like diuretics like chlorthalidone are excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following potential adverse reactions with Edarbyclor, azilsartan medoxomil, or chlorthalidone and similar agents are included in more detail in the Warnings and Precautions section of the label:</p><ul><li>Fetal toxicity [see section 4.4. Special warnings and precautions for use]</li><li>Hypotension in Volume- or Salt-Depleted Patients [see section 4.4. Special warnings and precautions for use]</li><li>Impaired Renal Function [see section 4.4. Special warnings and precautions for use]</li><li>Hypokalemia [see section 4.4. Special warnings and precautions for use]</li><li>Hyperuricemia [see section 4.4. Special warnings and precautions for use]</li></ul><p><strong><em>Clinical Trials Experience</em></strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Edarbyclor has been evaluated for safety in more than 3900 patients with hypertension; more than 700 patients were treated for at least 6 months and more than 280 for at least 1 year. Adverse reactions have generally been mild and transient in nature.</p><p>Common adverse reactions that occurred in the 8-week factorial design trial in at least 2% of Edarbyclor-treated patients and greater than azilsartan medoxomil or chlorthalidone are presented in Table 1.</p><p><strong>Table 1. Adverse Reactions Occurring at an Incidence of &ge;2% of Edarbyclor-treated Patients and &gt; Azilsartan medoxomil or Chlorthalidone</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Preferred Term</strong></p></td><td><p><strong>Azilsartan medoxomil 20, 40, 80 mg</strong></p><p><strong>(N=470)</strong></p></td><td><p><strong>Chlorthalidone</strong></p><p><strong>12.5, 25 mg</strong></p><p><strong>(N=316)</strong></p></td><td><p><strong>Edarbyclor</strong></p><p><strong>40/12.5, 40/25 mg (N=302)</strong></p></td></tr><tr><td><p>Dizziness</p></td><td><p>1.7%</p></td><td><p>1.9%</p></td><td><p>8.9%</p></td></tr><tr><td><p>Fatigue</p></td><td><p>0.6%</p></td><td><p>1.3%</p></td><td><p>2.0%</p></td></tr></tbody></table><p>Hypotension and syncope were reported in 1.7% and 0.3%, respectively, of patients treated with Edarbyclor.</p><p>Study discontinuation because of adverse reactions occurred in 8.3% of patients treated with the recommended doses of Edarbyclor compared with 3.2% of patients treated with azilsartan medoxomil and 3.2% of patients treated with chlorthalidone. The most common reasons for discontinuation of therapy with Edarbyclor were serum creatinine increased (3.6%) and dizziness (2.3%).</p><p>The adverse reaction profile obtained from 52 weeks of open-label combination therapy with azilsartan medoxomil plus chlorthalidone or Edarbyclor was similar to that observed during the double-blind, active controlled trials.</p><p>In 3 double-blind, active controlled, titration studies, in which Edarbyclor was titrated to higher doses in a step-wise manner, adverse reactions and discontinuations for adverse events were less frequent than in the fixed-dose factorial trial.</p><p><em>Azilsartan medoxomil</em></p><p>A total of 4814 patients were evaluated for safety when treated with azilsartan medoxomil at doses of 20, 40 or 80 mg in clinical trials. This includes 1704 patients treated for at least 6 months, of these, 588 were treated for at least 1 year. Generally, adverse reactions were mild, not dose related and similar regardless of age, gender and race.</p><p>Adverse reactions with a plausible relationship to treatment that have been reported with an incidence of &ge;0.3% and greater than placebo in more than 3300 patients treated with azilsartan medoxomil in controlled trials are listed below:</p><p><em>Gastrointestinal Disorders:</em> diarrhea, nausea</p><p><em>General Disorders and Administration Site Conditions:</em> asthenia, fatigue</p><p><em>Musculoskeletal and Connective Tissue Disorders:</em> muscle spasm</p><p><em>Nervous System Disorders:</em> dizziness, dizziness postural</p><p><em>Respiratory, Thoracic and Mediastinal Disorders:</em> cough</p><p><em>Chlorthalidone</em></p><p>The following adverse reactions have been observed in clinical trials of chlorthalidone: rash, headache, dizziness, GI upset, and elevations of uric acid and cholesterol.</p><p><em>Clinical Laboratory Findings with Edarbyclor</em></p><p>In the factorial design trial, clinically relevant changes in standard laboratory parameters were uncommon with administration of the recommended doses of Edarbyclor.</p><p><em>Renal parameters:</em> Increased blood creatinine is a known pharmacologic effect of renin-angiotensin aldosterone system (RAAS) blockers, such as ARBs and ACE inhibitors, and is related to the magnitude of blood pressure reduction. The incidence of consecutive increases of creatinine &ge;50% from baseline and &gt;ULN was 2.0% in patients treated with the recommended doses of Edarbyclor compared with 0.4% and 0.3% with azilsartan medoxomil and chlorthalidone, respectively. Elevations of creatinine were typically transient, or non-progressive and reversible, and associated with large blood pressure reductions.</p><p>Mean increases in blood urea nitrogen (BUN) were observed with Edarbyclor (5.3 mg/dL) compared with azilsartan medoxomil (1.5 mg/dL) and with chlorthalidone (2.5 mg/dL).</p><p><strong><em>Postmarketing Experience</em></strong></p><p>The following adverse reactions have been identified during the postmarketing use of EDARBYCLOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><ul><li>Nausea</li><li>Rash</li><li>Pruritus</li><li>Angioedema</li></ul><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available related to overdosage in humans.</p><p><strong><em>Azilsartan medoxomil</em></strong></p><p>Limited data are available related to overdosage in humans. During controlled clinical trials in healthy subjects, once daily doses up to 320 mg of azilsartan medoxomil were administered for 7 days and were well tolerated. In the event of an overdose, supportive therapy should be instituted as dictated by the patient&#39;s clinical status. Azilsartan is not dialyzable.</p><p><strong><em>Chlorthalidone</em></strong></p><p>Symptoms of acute overdosage include nausea, weakness, dizziness, and disturbances of electrolyte balance. The oral LD50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Edarbyclor</em></strong></p><p>Edarbyclor tablets have been shown to be effective in lowering blood pressure. Both azilsartan medoxomil and chlorthalidone lower blood pressure by reducing peripheral resistance but through complementary mechanisms.</p><p><strong><em>Azilsartan medoxomil</em></strong></p><p>Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. An azilsartan single dose equivalent to 32 mg azilsartan medoxomil inhibited the maximal pressor effect by approximately 90% at peak, and approximately 60% at 24 hours. Plasma angiotensin I and II concentrations and plasma renin activity increased while plasma aldosterone concentrations decreased after single and repeated administration of azilsartan medoxomil to healthy subjects; no clinically significant effects on serum potassium or sodium were observed.</p><p><strong><em>Chlorthalidone</em></strong></p><p>The diuretic effect of chlorthalidone occurs in approximately 2.6 hours and continues for up to 72 hours.</p><p><strong><em>Mechanism of Action</em></strong></p><p>The active ingredients of Edarbyclor target two separate mechanisms involved in blood pressure regulation. Azilsartan blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells. Chlorthalidone produces diuresis with increased excretion of sodium and chloride at the cortical diluting segment of the ascending limb of Henle&rsquo;s loop of the nephron.</p><p><em>Azilsartan medoxomil</em></p><p>Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principle pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.</p><p>An AT<sub>2</sub> receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT1 receptor than for the AT<sub>2</sub> receptor.</p><p><strong>&nbsp;</strong>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation.</p><p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure.</p><p><em>Chlorthalidone</em></p><p>Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the cortical diluting segment of the ascending limb of Henle&#39;s loop of the nephron. The diuretic effects of chlorthalildone lead to decreased extracellular fluid volume, plasma volume, cardiac output, total exchangeable sodium, glomerular filtration rate, and renal plasma flow. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.</p><p><strong>&nbsp;</strong><strong><em>Clinical Studies</em></strong></p><p>The antihypertensive effects of Edarbyclor have been demonstrated in a total of 5 randomized controlled studies, which included 4 double-blind, active-controlled studies and 1 open-label, long-term active-controlled study. The studies ranged from 8 weeks to 12 months in duration, at doses ranging from 20/12.5 mg to 80/25 mg once daily. A total of 5310 patients (3082 given Edarbyclor and 2228 given active comparator) with moderate or severe hypertension were studied. Overall, randomized patients had a mean age of 57 years, and included 52% males, 72% whites, 21% blacks, 15% with diabetes, 70% with mild or moderate renal impairment, and a mean BMI of 31.6 kg/m<sup>2</sup>.</p><p>An 8-week, multicenter, randomized, double-blind, active-controlled, parallel group factorial trial in patients with moderate to severe hypertension compared the effect on blood pressure of Edarbyclor with the respective monotherapies. The trial randomized 1714 patients with baseline systolic blood pressure between 160 and 190 mm Hg (mean 165 mm Hg) and a baseline diastolic blood pressure &lt;119 mm Hg (mean 95 mm Hg) to one of the 11 active treatment arms.</p><p>The 6 treatment combinations of azilsartan medoxomil 20, 40, or 80 mg and chlorthalidone 12.5 or 25 mg resulted in statistically significant reduction in systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (ABPM) (Table 2) and clinic measurement (Table 3) at trough compared with the respective individual monotherapies. The clinic blood pressure reductions appear larger than those observed with ABPM, because the former include a placebo effect, which was not directly measured. Most of the antihypertensive effect of Edarbyclor occurs within 1-2 weeks of dosing. The blood pressure lowering effect was maintained throughout the 24-hour period (Figure 3).</p><p><strong>Table 2. Mean Change from Baseline in Systolic/Diastolic Blood Pressure (mm Hg) as Measured by ABPM at Trough (22-24 Hours Post-Dose) at Week 8: Combination Therapy vs Monotherapy</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Chlorthalidone, mg</strong></p></td><td colspan="4"><p><strong>Azilsartan Medoxomil, mg</strong></p></td></tr><tr><td><p><strong>0</strong></p></td><td><p><strong>20</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>80</strong></p></td></tr><tr><td><p>0</p></td><td><p>N/A</p></td><td><p>-12 / -8</p></td><td><p>-13 / -7</p></td><td><p>-15 / -9</p></td></tr><tr><td><p>12.5</p></td><td><p>-13 / -7</p></td><td><p>-23 / -13</p></td><td><p>-24 / -14</p></td><td><p>-26 / -17</p></td></tr><tr><td><p>25</p></td><td><p>-16 / -8</p></td><td><p>-26 / -15</p></td><td><p>-30 / -17</p></td><td><p>-28 / -16</p></td></tr></tbody></table><p><strong>Table 3. Mean Change from Baseline in Clinic Systolic/Diastolic Blood Pressure (mm Hg) at Week 8: Combination Therapy vs Monotherapy</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Chlorthalidone, mg</strong></p></td><td colspan="4"><p><strong>Azilsartan Medoxomil, mg</strong></p></td></tr><tr><td><p><strong>0</strong></p></td><td><p><strong>20</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>80</strong></p></td></tr><tr><td><p>0</p></td><td><p>N/A</p></td><td><p>20 / -7</p></td><td><p>-23 / -9</p></td><td><p>-24 / -10</p></td></tr><tr><td><p>12.5</p></td><td><p>-21/ -7</p></td><td><p>-34 / -14</p></td><td><p>-37 / -16</p></td><td><p>-37 / -17</p></td></tr><tr><td><p>25</p></td><td><p>-27 / -9</p></td><td><p>-37/ -16</p></td><td><p>-40 / -17</p></td><td><p>-40 / -19</p></td></tr></tbody></table><p><strong>Figure 2. Mean Change from Baseline at Week 8 in Ambulatory Systolic Blood Pressure (mm Hg) by Treatment and Hour</strong></p><p>Edarbyclor was effective in reducing blood pressure regardless of age, gender, or race.</p><p>Edarbyclor was effective in treating black patients (usually a low-renin population).</p><p>In a 12-week, double-blind forced-titration trial, Edarbyclor 40/25 mg was statistically superior (P&lt;0.001) to olmesartan medoxomil &ndash; hydrochlorothiazide (OLM/HCTZ) 40/25 mg in reducing systolic blood pressure in patients with moderate to severe hypertension (Table 4). Similar results were observed in all subgroups, including age, gender, or race of patients.</p><p><strong>Table 4. Mean Change in Systolic/Diastolic Blood Pressure (mm Hg) at Week 12</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:754px"><tbody><tr><td style="width:388px"><p><strong>&nbsp;</strong></p></td><td style="width:182px"><p><strong>Edarbyclor 40/25 mg</strong></p><p><strong>N=355</strong></p></td><td style="width:181px"><p><strong>OLM/HCTZ 40/25 mg</strong></p><p><strong>N=364</strong></p></td></tr><tr><td style="width:388px"><p>Clinic</p><p>(Mean Baseline 165/96 mm Hg)</p></td><td style="width:182px"><p>-43 / -19</p></td><td style="width:181px"><p>-37 / -16</p></td></tr><tr><td style="width:388px"><p>Trough by ABPM (22-24 hours) (Mean Baseline 153/92 mm Hg)</p></td><td style="width:182px"><p>-33 / -20</p></td><td style="width:181px"><p>-26 / -16</p></td></tr></tbody></table><p><strong>&nbsp;</strong>Edarbyclor lowered blood pressure more effectively than OLM/HCTZ at each hour of the 24-hour interdosing period as measured by ABPM.</p><p><em>Cardiovascular Outcomes</em></p><p>There are no trials of Edarbyclor demonstrating reductions in cardiovascular risk in patients with hypertension; however, trials with chlorthalidone and at least one drug pharmacologically similar to azilsartan medoxomil have demonstrated such benefits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Edarbyclor</em></strong></p><p>Following oral administration of Edarbyclor, peak plasma concentrations of azilsartan and chlorthalidone are reached at 3 and 1 hours, respectively. The rate (C<sub>max</sub> and T<sub>max</sub>) and extent (AUC) of absorption of azilsartan are similar when it is administered alone or with chlorthalidone. The extent (AUC) of absorption of chlorthalidone is similar when it is administered alone or with azilsartan medoxomil; however, the C<sub>max </sub>of chlorthalidone from Edarbyclor was 47% higher. The elimination half-lives of azilsartan and chlorthalidone are approximately 12 hours and 45 hours, respectively.</p><p>There is no clinically significant effect of food on the bioavailability of Edarbyclor.</p><p><strong><em>Azilsartan medoxomil</em></strong></p><p><em>Absorption: Azilsartan</em> medoxomil is rapidly hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption. Azilsartan medoxomil is not detected in plasma after oral administration. Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing.</p><p>The estimated absolute bioavailability of azilsartan following administration of azilsartan medoxomil is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma concentrations (C<sub>max</sub>) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan.</p><p><em>Distribution</em></p><p>Azilsartan medoxomil: The volume of distribution of azilsartan is approximately 16L. Azilsartan is highly bound to human plasma proteins (&gt;99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well above the range achieved with recommended doses.</p><p>In rats, minimal azilsartan-associated radioactivity crossed the blood-brain barrier. Azilsartan passed across the placental barrier in pregnant rats and was distributed to the fetus.</p><p>Chlorthalidone: In whole blood, chlorthalidone is predominantly bound to erythrocyte carbonic anhydrase. In the plasma, approximately 75% of chlorthalidone is bound to plasma proteins, 58% of the drug being bound to albumin.</p><p><em>Metabolism and Elimination</em></p><p>Azilsartan medoxomil: Azilsartan is metabolized to two primary metabolites. The major metabolite in plasma is formed by O-dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately 50% and less than 1% of azilsartan, respectively. M-I and MII do not contribute to the pharmacologic activity of azilsartan medoxomil. The major enzyme responsible for azilsartan metabolism is CYP2C9.</p><p>Following an oral dose of 14C-labeled azilsartan medoxomil, approximately 55% of radioactivity was recovered in feces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min. Steady-state levels of azilsartan are achieved within 5 days and no accumulation in plasma occurs with repeated once-daily dosing.</p><p>Chlorthalidone: The major portion of the drug is excreted unchanged by the kidneys. Nonrenal routes of elimination have yet to be clarified. Data are not available regarding percentage of dose as unchanged drug and metabolites, concentration of the drug in body fluids, degree of uptake by a particular organ or in the fetus, or passage across the blood-brain barrier.</p><p><em>Special Populations</em></p><p>Azilsartan medoxomil: The effect of demographic and functional factors on the pharmacokinetics of azilsartan was studied in single and multiple dose studies. Pharmacokinetic measures indicating the magnitude of the effect on azilsartan are presented in Figure 2 as change relative to reference (test/reference).</p><p><strong>Figure 3. Impact of intrinsic factors on the pharmacokinetics of azilsartan</strong></p><p><img alt="" width="534" height="433" src="data:image/png;base64,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" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Carcinogenesis, Mutagenesis, Impairment of Fertility</em></strong></p><p>No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of azilsartan medoxomil and chlorthalidone. However, these studies have been conducted for azilsartan medoxomil alone.</p><p><em>Azilsartan medoxomil</em></p><p>Carcinogenesis: Azilsartan medoxomil was not carcinogenic when assessed in 26-week transgenic (Tg.rasH2) mouse and 2-year rat studies. The highest doses tested (450 mg azilsartan medoxomil/kg/day in the mouse and 600 mg azilsartan medoxomil/kg/day in the rat) produced exposures to azilsartan that are 12 (mice) and 27 (rats) times the average exposure to azilsartan in humans given the maximum recommended human dose (MRHD, 80 mg azilsartan medoxomil/day). M-II was not carcinogenic when assessed in 26-week Tg.rasH2 mouse and 2-year rat studies. The highest doses tested (approximately 8000 mg M-II/kg/day (males) and 11,000 mg M-II/kg/day (females) in the mouse and 1000 mg M-II/kg/day (males) and up to 3000 mg M-II/kg/day (females) in the rat) produced exposures that are, on average, about 30 (mice) and 7 (rats) times the average exposure to M-II in humans at the MRHD.</p><p>Mutagenesis: Azilsartan medoxomil, azilsartan, and M-II were positive for structural aberrations in the Chinese Hamster Lung Cytogenic Assay. In this assay, structural chromosomal aberrations were observed with the prodrug, azilsartan medoxomil, without metabolic activation. The active moiety, azilsartan, was also positive in this assay both with and without metabolic activation. The major human metabolite, M-II was also positive in this assay during a 24-hr assay without metabolic activation.</p><p>Azilsartan medoxomil, azilsartan, and M-II were devoid of genotoxic potential in the Ames reverse mutation assay with Salmonella typhimurium and Escherichia coli, the in vitro Chinese Hamster Ovary Cell forward mutation assay, the in vitro mouse lymphoma (tk) gene mutation test, the ex vivo unscheduled DNA synthesis test, and the in vivo mouse and/or rat bone marrow micronucleus assay.</p><p>Impairment of Fertility: There was no effect of azilsartan medoxomil on the fertility of male or female rats at oral doses of up to 1000 mg azilsartan medoxomil/kg/day [6000 mg/m<sup>2</sup> (approximately 122 times the MRHD of 80 mg azilsartan medoxomil/60 kg on a mg/m<sup>2</sup> basis)]. Fertility of rats also was unaffected at doses of up to 3000 mg M-II/kg/day.</p><p><strong><em>Animal Toxicology and/or Pharmacology</em></strong></p><p><em>Edarbyclor</em></p><p>The safety profiles of azilsartan medoxomil and chlorthalidone monotherapy have been individually established. To characterize the toxicological profile for Edarbyclor, a 13-week repeat-dose toxicity study was conducted in rats. The results of this study indicated that the combined administration of azilsartan medoxomil, M-II, and chlorthalidone resulted in increased exposures to chlorthalidone.</p><p>Pharmacologically-mediated toxicity, including suppression of body weight gain and decreased food consumption in male rats, and increases in blood urea nitrogen in both sexes, was enhanced by coadministration of azilsartan medoxomil, M-II, and chlorthalidone. With the exception of these findings, there were no toxicologically synergistic effects in this study.</p><p>In an embryo-fetal developmental study in rats, there was no teratogenicity or increase in fetal mortality in the litters of dams receiving azilsartan medoxomil, M-II and chlorthalidone concomitantly at maternally toxic doses.</p><p><em>Azilsartan medoxomil</em></p><p>Reproductive Toxicology: In peri- and postnatal rat development studies, adverse effects on pup viability, delayed incisor eruption and dilatation of the renal pelvis along with hydronephrosis were seen when azilsartan medoxomil was administered to pregnant and nursing rats at 1.2 times the MRHD on a mg/m<sup>2</sup> basis. Reproductive toxicity studies indicated that azilsartan medoxomil was not teratogenic when administered at oral doses up to 1000 mg azilsartan medoxomil/kg/day to pregnant rats (122 times the MRHD on a mg/m<sup>2</sup> basis) or up to 50 mg azilsartan medoxomil/kg/day to pregnant rabbits (12 times the MRHD on a mg/m<sup>2</sup> basis). M-II also was not teratogenic in rats or rabbits at doses up to 3000 mg MII/kg/day. Azilsartan crossed the placenta and was found in the fetuses of pregnant rats and was excreted into the milk of lactating rats.</p><p><em>Chlorthalidone</em></p><p>Reproductive toxicology: Reproduction studies have been performed in the rat and the rabbit at doses up to 420 times the human dose and have revealed no evidence of harm to the fetus. Thiazides cross the placental barrier and appear in cord blood.</p><p>Pharmacology: Biochemical studies in animals have suggested reasons for the prolonged effect of chlorthalidone. Absorption from the gastrointestinal tract is slow because of its low solubility. After passage to the liver, some of the drug enters the general circulation, while some is excreted in the bile, to be reabsorbed later. In the general circulation, it is distributed widely to the tissue, but is taken up in highest concentrations by the kidneys, where amounts have been found 72 hours after ingestion, long after it has disappeared from other tissues. The drug is excreted unchanged in the urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><ul><li>Mannitol</li><li>Microcrystalline cellulose</li><li>Fumaric acid</li><li>Sodium hydroxide</li><li>Hydroxypropyl cellulose</li><li>Crospovidone</li><li>Magnesium stearate</li></ul><p><u>Tablet coat:</u></p><ul><li>Hypromellose</li><li>Talc</li><li>Titanium dioxide</li><li>Ferric oxide red</li><li>Polyethylene glycol</li></ul><p><u>Printing ink:</u></p><ul><li>Opacode black.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Keep the container tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carton containing desiccated aluminum/aluminum blister packs.</p><p>Pack size: 28 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Edarbyclor is moisture sensitive, dispense and store Edarbyclor in its original container to protect Edarbyclor from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: jpimedical@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 August 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>